Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

BACKGROUND: Natalizumab, a highly specific α4-integrin antagonist, , has recently been registered across the Middle East and North Africa region. It improves clinical and magnetic resonance imaging (MRI) outcomes and reduces the rate of relapse and disability progression in relapsing-remitting multi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Alroughani, Raed A, Aref, Hany M, Bohlega, Saeed A, Dahdaleh, Maurice P, Feki, Imed, Al Jumah, Mohammed A, Al-Kawi, Muhammad Z, Koussa, Salam F, Sahraian, Mohamad A, Alsharoqi, Isa A, Yamout, Bassem I
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3927624/
https://ncbi.nlm.nih.gov/pubmed/24521176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-14-27
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados